Report Detail
Global Eosinophilic Esophagitis Drug Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032
- RnM4657394 |
- 20 March, 2026 |
- Global |
- 117 Pages |
- GIR |
- Pharma & Healthcare
According to our (Global Info Research) latest study, the global Eosinophilic Esophagitis Drug market size was valued at US$ 259 million in 2025 and is forecast to a readjusted size of US$ 372 million by 2032 with a CAGR of 5.4% during review period.
Eosinophilic esophagitis drugs are specialized medications for the treatment of eosinophilic esophagitis (EoE), a chronic immune-mediated inflammatory disease of the esophagus characterized by difficulty swallowing, food impaction, and chest pain. These drugs alleviate symptoms and promote tissue repair by suppressing local inflammation, modulating immune responses, or targeting eosinophil activity. Current therapies include topical or systemic corticosteroids, immunomodulators, and emerging targeted biologics. Recent research focuses on enhancing efficacy, safety, and patient adherence while implementing personalized treatment strategies to address recurrence and chronic disease management. With increased awareness and improved diagnosis, eosinophilic esophagitis drugs are emerging as an innovative segment in the gastrointestinal therapeutics market.In 2024, global Eosinophilic esophagitis drugs production reached approximately 24.4 m units , with an average global market price of around US$ 10 perunit.The average gross profit margin of this product is around 50%.
The eosinophilic esophagitis drug market is driven by increased disease diagnosis rates, rising demand for chronic disease management, and growing investment in biologic drug development. Annual reports of leading pharmaceutical companies indicate continuous optimization of efficacy and safety through clinical trials and innovative molecule development to meet diverse patient needs. With enhanced patient awareness and standardized diagnosis and treatment protocols, prescription volumes are steadily increasing. Additionally, policy attention to chronic gastrointestinal diseases and expanded insurance coverage provide market support for high-value drugs, fostering industry growth and attracting investment.Despite significant potential, the industry faces long regulatory approval cycles, high R&D costs, and the challenge of balancing efficacy and safety. EoE is a relatively rare immune-mediated disease, limiting patient populations and complicating clinical trial recruitment. High-cost targeted biologics face hurdles in market access and insurance coverage. Long-term use may carry side effect risks, and the recurrent nature of the disease requires continuous innovation in sustained efficacy and patient adherence management.Clinical demand is increasingly precise and personalized. Gastroenterologists and allergists prefer adjustable, highly targeted, and low-side-effect therapies. With growing patient self-management awareness and the proliferation of telemedicine and digital follow-up, treatment is shifting toward personalized combination therapies and long-term management models. The concentration of demand in outpatient and specialty centers provides market opportunities for innovative drugs and high-value treatment services.Key raw materials for eosinophilic esophagitis drugs include active pharmaceutical ingredients (such as corticosteroid molecules, targeted antibodies, or small-molecule immunomodulators), pharmaceutical excipients and formulation carriers, as well as expression systems and purification reagents for biologics. Annual reports indicate that high-purity active ingredient supply is concentrated, with some critical materials dependent on specific suppliers or cross-border imports, creating price volatility and supply chain risks. Establishing long-term supplier relationships, optimizing production processes, and diversifying raw material sources allow companies to ensure stable supply and support the development of novel delivery systems and combination therapy products.
This report is a detailed and comprehensive analysis for global Eosinophilic Esophagitis Drug market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Eosinophilic Esophagitis Drug market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2021-2032
Global Eosinophilic Esophagitis Drug market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2021-2032
Global Eosinophilic Esophagitis Drug market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2021-2032
Global Eosinophilic Esophagitis Drug market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (USD/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Eosinophilic Esophagitis Drug
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Eosinophilic Esophagitis Drug market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include AstraZeneca, GSK, Bayer, Adare Pharmaceuticals, DBV Technologies, Dr. Falk Pharma, Quorum Innovations, Takeda, Calypso, Celgene, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Eosinophilic Esophagitis Drug market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Budesonide
Fluticasone
PPI
Others
Market segment by Application
Hospitals
Clinics
Drugstore
Major players covered
AstraZeneca
GSK
Bayer
Adare Pharmaceuticals
DBV Technologies
Dr. Falk Pharma
Quorum Innovations
Takeda
Calypso
Celgene
Regeneron
Luoxin Pharma
LIVZON
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Eosinophilic Esophagitis Drug product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Eosinophilic Esophagitis Drug, with price, sales quantity, revenue, and global market share of Eosinophilic Esophagitis Drug from 2021 to 2026.
Chapter 3, the Eosinophilic Esophagitis Drug competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Eosinophilic Esophagitis Drug breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Eosinophilic Esophagitis Drug market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Eosinophilic Esophagitis Drug.
Chapter 14 and 15, to describe Eosinophilic Esophagitis Drug sales channel, distributors, customers, research findings and conclusion.
1 Market Overview
- 1.1 Product Overview and Scope
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Market Analysis by Type
- 1.3.1 Overview: Global Eosinophilic Esophagitis Drug Consumption Value by Type: 2021 Versus 2025 Versus 2032
- 1.3.2 Budesonide
- 1.3.3 Fluticasone
- 1.3.4 PPI
- 1.3.5 Others
- 1.4 Market Analysis by Application
- 1.4.1 Overview: Global Eosinophilic Esophagitis Drug Consumption Value by Application: 2021 Versus 2025 Versus 2032
- 1.4.2 Hospitals
- 1.4.3 Clinics
- 1.4.4 Drugstore
- 1.5 Global Eosinophilic Esophagitis Drug Market Size & Forecast
- 1.5.1 Global Eosinophilic Esophagitis Drug Consumption Value (2021 & 2025 & 2032)
- 1.5.2 Global Eosinophilic Esophagitis Drug Sales Quantity (2021-2032)
- 1.5.3 Global Eosinophilic Esophagitis Drug Average Price (2021-2032)
2 Manufacturers Profiles
- 2.1 AstraZeneca
- 2.1.1 AstraZeneca Details
- 2.1.2 AstraZeneca Major Business
- 2.1.3 AstraZeneca Eosinophilic Esophagitis Drug Product and Services
- 2.1.4 AstraZeneca Eosinophilic Esophagitis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.1.5 AstraZeneca Recent Developments/Updates
- 2.2 GSK
- 2.2.1 GSK Details
- 2.2.2 GSK Major Business
- 2.2.3 GSK Eosinophilic Esophagitis Drug Product and Services
- 2.2.4 GSK Eosinophilic Esophagitis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.2.5 GSK Recent Developments/Updates
- 2.3 Bayer
- 2.3.1 Bayer Details
- 2.3.2 Bayer Major Business
- 2.3.3 Bayer Eosinophilic Esophagitis Drug Product and Services
- 2.3.4 Bayer Eosinophilic Esophagitis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.3.5 Bayer Recent Developments/Updates
- 2.4 Adare Pharmaceuticals
- 2.4.1 Adare Pharmaceuticals Details
- 2.4.2 Adare Pharmaceuticals Major Business
- 2.4.3 Adare Pharmaceuticals Eosinophilic Esophagitis Drug Product and Services
- 2.4.4 Adare Pharmaceuticals Eosinophilic Esophagitis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.4.5 Adare Pharmaceuticals Recent Developments/Updates
- 2.5 DBV Technologies
- 2.5.1 DBV Technologies Details
- 2.5.2 DBV Technologies Major Business
- 2.5.3 DBV Technologies Eosinophilic Esophagitis Drug Product and Services
- 2.5.4 DBV Technologies Eosinophilic Esophagitis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.5.5 DBV Technologies Recent Developments/Updates
- 2.6 Dr. Falk Pharma
- 2.6.1 Dr. Falk Pharma Details
- 2.6.2 Dr. Falk Pharma Major Business
- 2.6.3 Dr. Falk Pharma Eosinophilic Esophagitis Drug Product and Services
- 2.6.4 Dr. Falk Pharma Eosinophilic Esophagitis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.6.5 Dr. Falk Pharma Recent Developments/Updates
- 2.7 Quorum Innovations
- 2.7.1 Quorum Innovations Details
- 2.7.2 Quorum Innovations Major Business
- 2.7.3 Quorum Innovations Eosinophilic Esophagitis Drug Product and Services
- 2.7.4 Quorum Innovations Eosinophilic Esophagitis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.7.5 Quorum Innovations Recent Developments/Updates
- 2.8 Takeda
- 2.8.1 Takeda Details
- 2.8.2 Takeda Major Business
- 2.8.3 Takeda Eosinophilic Esophagitis Drug Product and Services
- 2.8.4 Takeda Eosinophilic Esophagitis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.8.5 Takeda Recent Developments/Updates
- 2.9 Calypso
- 2.9.1 Calypso Details
- 2.9.2 Calypso Major Business
- 2.9.3 Calypso Eosinophilic Esophagitis Drug Product and Services
- 2.9.4 Calypso Eosinophilic Esophagitis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.9.5 Calypso Recent Developments/Updates
- 2.10 Celgene
- 2.10.1 Celgene Details
- 2.10.2 Celgene Major Business
- 2.10.3 Celgene Eosinophilic Esophagitis Drug Product and Services
- 2.10.4 Celgene Eosinophilic Esophagitis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.10.5 Celgene Recent Developments/Updates
- 2.11 Regeneron
- 2.11.1 Regeneron Details
- 2.11.2 Regeneron Major Business
- 2.11.3 Regeneron Eosinophilic Esophagitis Drug Product and Services
- 2.11.4 Regeneron Eosinophilic Esophagitis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.11.5 Regeneron Recent Developments/Updates
- 2.12 Luoxin Pharma
- 2.12.1 Luoxin Pharma Details
- 2.12.2 Luoxin Pharma Major Business
- 2.12.3 Luoxin Pharma Eosinophilic Esophagitis Drug Product and Services
- 2.12.4 Luoxin Pharma Eosinophilic Esophagitis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.12.5 Luoxin Pharma Recent Developments/Updates
- 2.13 LIVZON
- 2.13.1 LIVZON Details
- 2.13.2 LIVZON Major Business
- 2.13.3 LIVZON Eosinophilic Esophagitis Drug Product and Services
- 2.13.4 LIVZON Eosinophilic Esophagitis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.13.5 LIVZON Recent Developments/Updates
3 Competitive Environment: Eosinophilic Esophagitis Drug by Manufacturer
- 3.1 Global Eosinophilic Esophagitis Drug Sales Quantity by Manufacturer (2021-2026)
- 3.2 Global Eosinophilic Esophagitis Drug Revenue by Manufacturer (2021-2026)
- 3.3 Global Eosinophilic Esophagitis Drug Average Price by Manufacturer (2021-2026)
- 3.4 Market Share Analysis (2025)
- 3.4.1 Producer Shipments of Eosinophilic Esophagitis Drug by Manufacturer Revenue ($MM) and Market Share (%): 2025
- 3.4.2 Top 3 Eosinophilic Esophagitis Drug Manufacturer Market Share in 2025
- 3.4.3 Top 6 Eosinophilic Esophagitis Drug Manufacturer Market Share in 2025
- 3.5 Eosinophilic Esophagitis Drug Market: Overall Company Footprint Analysis
- 3.5.1 Eosinophilic Esophagitis Drug Market: Region Footprint
- 3.5.2 Eosinophilic Esophagitis Drug Market: Company Product Type Footprint
- 3.5.3 Eosinophilic Esophagitis Drug Market: Company Product Application Footprint
- 3.6 New Market Entrants and Barriers to Market Entry
- 3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
- 4.1 Global Eosinophilic Esophagitis Drug Market Size by Region
- 4.1.1 Global Eosinophilic Esophagitis Drug Sales Quantity by Region (2021-2032)
- 4.1.2 Global Eosinophilic Esophagitis Drug Consumption Value by Region (2021-2032)
- 4.1.3 Global Eosinophilic Esophagitis Drug Average Price by Region (2021-2032)
- 4.2 North America Eosinophilic Esophagitis Drug Consumption Value (2021-2032)
- 4.3 Europe Eosinophilic Esophagitis Drug Consumption Value (2021-2032)
- 4.4 Asia-Pacific Eosinophilic Esophagitis Drug Consumption Value (2021-2032)
- 4.5 South America Eosinophilic Esophagitis Drug Consumption Value (2021-2032)
- 4.6 Middle East & Africa Eosinophilic Esophagitis Drug Consumption Value (2021-2032)
5 Market Segment by Type
- 5.1 Global Eosinophilic Esophagitis Drug Sales Quantity by Type (2021-2032)
- 5.2 Global Eosinophilic Esophagitis Drug Consumption Value by Type (2021-2032)
- 5.3 Global Eosinophilic Esophagitis Drug Average Price by Type (2021-2032)
6 Market Segment by Application
- 6.1 Global Eosinophilic Esophagitis Drug Sales Quantity by Application (2021-2032)
- 6.2 Global Eosinophilic Esophagitis Drug Consumption Value by Application (2021-2032)
- 6.3 Global Eosinophilic Esophagitis Drug Average Price by Application (2021-2032)
7 North America
- 7.1 North America Eosinophilic Esophagitis Drug Sales Quantity by Type (2021-2032)
- 7.2 North America Eosinophilic Esophagitis Drug Sales Quantity by Application (2021-2032)
- 7.3 North America Eosinophilic Esophagitis Drug Market Size by Country
- 7.3.1 North America Eosinophilic Esophagitis Drug Sales Quantity by Country (2021-2032)
- 7.3.2 North America Eosinophilic Esophagitis Drug Consumption Value by Country (2021-2032)
- 7.3.3 United States Market Size and Forecast (2021-2032)
- 7.3.4 Canada Market Size and Forecast (2021-2032)
- 7.3.5 Mexico Market Size and Forecast (2021-2032)
8 Europe
- 8.1 Europe Eosinophilic Esophagitis Drug Sales Quantity by Type (2021-2032)
- 8.2 Europe Eosinophilic Esophagitis Drug Sales Quantity by Application (2021-2032)
- 8.3 Europe Eosinophilic Esophagitis Drug Market Size by Country
- 8.3.1 Europe Eosinophilic Esophagitis Drug Sales Quantity by Country (2021-2032)
- 8.3.2 Europe Eosinophilic Esophagitis Drug Consumption Value by Country (2021-2032)
- 8.3.3 Germany Market Size and Forecast (2021-2032)
- 8.3.4 France Market Size and Forecast (2021-2032)
- 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
- 8.3.6 Russia Market Size and Forecast (2021-2032)
- 8.3.7 Italy Market Size and Forecast (2021-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Eosinophilic Esophagitis Drug Sales Quantity by Type (2021-2032)
- 9.2 Asia-Pacific Eosinophilic Esophagitis Drug Sales Quantity by Application (2021-2032)
- 9.3 Asia-Pacific Eosinophilic Esophagitis Drug Market Size by Region
- 9.3.1 Asia-Pacific Eosinophilic Esophagitis Drug Sales Quantity by Region (2021-2032)
- 9.3.2 Asia-Pacific Eosinophilic Esophagitis Drug Consumption Value by Region (2021-2032)
- 9.3.3 China Market Size and Forecast (2021-2032)
- 9.3.4 Japan Market Size and Forecast (2021-2032)
- 9.3.5 South Korea Market Size and Forecast (2021-2032)
- 9.3.6 India Market Size and Forecast (2021-2032)
- 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
- 9.3.8 Australia Market Size and Forecast (2021-2032)
10 South America
- 10.1 South America Eosinophilic Esophagitis Drug Sales Quantity by Type (2021-2032)
- 10.2 South America Eosinophilic Esophagitis Drug Sales Quantity by Application (2021-2032)
- 10.3 South America Eosinophilic Esophagitis Drug Market Size by Country
- 10.3.1 South America Eosinophilic Esophagitis Drug Sales Quantity by Country (2021-2032)
- 10.3.2 South America Eosinophilic Esophagitis Drug Consumption Value by Country (2021-2032)
- 10.3.3 Brazil Market Size and Forecast (2021-2032)
- 10.3.4 Argentina Market Size and Forecast (2021-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Eosinophilic Esophagitis Drug Sales Quantity by Type (2021-2032)
- 11.2 Middle East & Africa Eosinophilic Esophagitis Drug Sales Quantity by Application (2021-2032)
- 11.3 Middle East & Africa Eosinophilic Esophagitis Drug Market Size by Country
- 11.3.1 Middle East & Africa Eosinophilic Esophagitis Drug Sales Quantity by Country (2021-2032)
- 11.3.2 Middle East & Africa Eosinophilic Esophagitis Drug Consumption Value by Country (2021-2032)
- 11.3.3 Turkey Market Size and Forecast (2021-2032)
- 11.3.4 Egypt Market Size and Forecast (2021-2032)
- 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
- 11.3.6 South Africa Market Size and Forecast (2021-2032)
12 Market Dynamics
- 12.1 Eosinophilic Esophagitis Drug Market Drivers
- 12.2 Eosinophilic Esophagitis Drug Market Restraints
- 12.3 Eosinophilic Esophagitis Drug Trends Analysis
- 12.4 Porters Five Forces Analysis
- 12.4.1 Threat of New Entrants
- 12.4.2 Bargaining Power of Suppliers
- 12.4.3 Bargaining Power of Buyers
- 12.4.4 Threat of Substitutes
- 12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
- 13.1 Raw Material of Eosinophilic Esophagitis Drug and Key Manufacturers
- 13.2 Manufacturing Costs Percentage of Eosinophilic Esophagitis Drug
- 13.3 Eosinophilic Esophagitis Drug Production Process
- 13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
- 14.1 Sales Channel
- 14.1.1 Direct to End-User
- 14.1.2 Distributors
- 14.2 Eosinophilic Esophagitis Drug Typical Distributors
- 14.3 Eosinophilic Esophagitis Drug Typical Customers
15 Research Findings and Conclusion
16 Appendix
- 16.1 Methodology
- 16.2 Research Process and Data Source
Summary:
Get latest Market Research Reports on Eosinophilic Esophagitis Drug. Industry analysis & Market Report on Eosinophilic Esophagitis Drug is a syndicated market report, published as Global Eosinophilic Esophagitis Drug Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Eosinophilic Esophagitis Drug market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
